Three different WT KRAS CRC PDX tumors representing the three CMS sub-types were treated with either vehicle (PBS), a small molecule glutaminase inhibitor (CB−839), an EGFR-neutralizing monoclonal antibody (αEGFR), or a combination. This evidence concerns the gene KRAS and colorectal carcinoma.